Clinical Research Directory
Browse clinical research sites, groups, and studies.
Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
Sponsor: Central Hospital, Nancy, France
Summary
Systemic Lupus Erythematosus (SLE) is a chronic invalidating chronic condition, with potential articular, cutaneous, renal, and neurologic involvement. Its pathophysiology is complex, and involves genetic, environmental and hormonal factors, leading to tolerance rupture. Among regulatory cells, Myeloid Derived Suppressor Cells (MDSCs) have been described as being increased during SLE, furthermore during flares. MDSCs are defined phenotypically as being HLA-DR-CD3-CD19-CD33+CD11b+, and either CD14+ (Monocytic MDSCs), CD15+ (Granulocytic MDSCs), or CD14-CD15- (Early-stage MDSCs). However, data regarding their immunosuppressive properties are conflicting, some studies identifying regulatory properties, while other have demonstrated a pro-inflammatory involvement through the induction of Th17 lymphocytes. The objectives of this study is to assess the involvement of MDSC in SLE through accurate phenotypical and functional assessment, as well as characterizing their immunometabolic profile, and to identify innovative therapeutic strategies.
Official title: Involvement of Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2022-07-15
Completion Date
2027-01-15
Last Updated
2022-06-21
Healthy Volunteers
No
Conditions
Locations (1)
Thomas Moulinet
Vandœuvre-lès-Nancy, Lorraine, France